AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with polyangiitis.
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with polyangiitis.
What's Your Reaction?
